Our previous studies suggested that salidroside could alleviate hepatic steatosis in type 2
diabetic C57BLKS/Leprdb (db/db) mice. The aim of the present study was to evaluate the …

Non-alcoholic fatty liver disease (NAFLD) causes liver dysfunction and is associated with
obesity and type 2 diabetes. Chronic inflammation is associated not only with the …

The prevalence of non-alcoholic fatty liver disease (NAFLD) is much higher in diabetic and
obese individuals. Combined exposure of high-fat diet (HFD) and single low-dose …

Objective Celastrol was recently identified as a potential novel treatment for obesity.
However, the effect of Celastrol on nonalcoholic fatty liver disease (NAFLD) remains elusive …

Diabetes mellitus (DM) is a factor with great risk in the course of non-alcoholic fatty liver
disease (NAFLD) due to its high glucotoxicity and lipotoxicity. Trilobatin, a glycosylated …

Non-alcoholic fatty liver disease (NAFLD) has high occurrence in the global world, which
poses serious threats to human health. Salvianolic acid B (SalB), an extract of the root of …

Liraglutide, a glucagon-like peptide 1 (GLP-1) analogue, could reverse NAFLD-induced liver
damage by improving metabolic profiles, but the exact molecular mechanism has not been …

Salvianolic acid A (SalA), one of the most efficacious polyphenol compounds extracted from
Radix Salvia miltiorrhiza (Danshen), has been shown to possess many potential …

Silymarin is a potent antioxidant medicine and has been widely used for the treatment of
liver diseases over 30 years. Recent studies suggest that silymarin may benefit patients with …

Non-alcoholic fatty liver disease (NAFLD) is a major public health concern worldwide. The
aim of the present study was to observe the effect of diosgenin on NAFLD and investigate …